Evonik Establishes New Health Care Business Line
Evonik Industries AG recently announced it will combine its business in custom manufacturing of APIs (exclusive synthesis), pharmaceutical amino acids (Rexim) and pharmaceutical polymers in the new Health Care Business Line effective September 2011. The newly formed business line will be part of the Health & Nutrition Business Unit, headed by Dr. Reiner Beste.
“The merger strengthens our distribution, research, technical service, and production network. This means our products and services will be equally represented in key pharmaceutical markets in Europe,
Success factors for specialty chemical companies in the pharmaceutical market include global market access, a broad innovation platform, and production in accordance with the cGMP pharmaceutical standard.
“By concentrating our pharmaceutical activities in the Health Care Business Line, we enhance our performance in all three areas,” noted Dr. Beste. “This creates the framework for further strategic developments and the targeted advancement of partnerships with key customers.”
The Health Care Business Line will be divided into three product lines: Pharma Polymers with the brands EUDRAGIT and RESOMER under the management of Dr. Thomas Riermeier, Exclusive Synthesis under the management of Dr. Klaus Stingl, and Rexim under the management of Dr. Thomas Hermann.
The Pharma Polymers Product Line is a leading developer and manufacturer of functional pharmaceutical excipients for oral and depot formulations and a provider of solutions to the healthcare industry for drug and medical device functionality. The Pharma Polymers portfolio includes acrylic copolymers marketed under the brand name EUDRAGIT, bioresorbable poly(lactic-co-glycolic acid) copolymers marketed under the brand name RESOMER as well as advanced formulation services for oral and parenteral dosage forms.
The Exclusive Synthesis Product Line focuses on the manufacture of custom-tailored, high-quality advanced GMP-intermediates and patented API and high-potency APIs (HPAPI) for the pharmaceutical industry, from clinical stage all the way to commercialization. The global production and research network of the product line offers a seamless service portfolio, ranging from the development of syntheses at the laboratory-scale to commercial-scale production in facilities certified by the US FDA.
The Rexim Product Line is a significant producer of amino acids, peptides, and amino acid derivatives, supplied in pharmaceutical and food-grade qualities. These products are primarily used in the pharmaceutical industry, including in infusion solutions, in cell cultures, and to manufacture APIs for the treatment of high blood pressure and diabetes, but also have applications in the cosmetics and food industry. The strengths of Evonik include its global distribution network and cGMP-compliant manufacturing across the entire supply chain, ranging all the way to cGMP-compliant amino acid purification.
Total Page Views: 1310
